Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months

      Awaiting FDA Decision to Accept NDA Submission for Review

Conference Call and Webcast Today, February 7th, at 4:30 p.m. ET

WATERTOWN, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today reported financial results for its fiscal 2018 second quarter and six months ended December 31, 2017 and provided an update on its continued operating progress. 

Recent Operating Highlights  

  • Submitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Durasert™ three-year treatment for posterior segment uveitis
  • Obtained from the FDA a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $2.4 million in connection with the NDA filing
  • Newly released second Phase 3 study data for Durasert three-year treatment for posterior segment uveitis continued to demonstrate positive efficacy and safety profile at 12 months
  • Presented Phase 3 data at several medical conferences, including the American Academy of Ophthalmology (AAO) annual meeting and the American Uveitis Society (AUS) winter meeting
  • Reported positive Phase 1 knee osteoarthritis pain study data indicating that the implant was well tolerated and showed potential for pain reduction through the six-month study period

"We achieved several milestones in the fiscal second quarter and the past few weeks and continue to make material progress in the transformation of pSivida into a fully integrated commercial stage pharmaceutical enterprise," commented Nancy Lurker, President & CEO.  "Our highest priority was the NDA submission for Durasert three-year treatment for posterior segment uveitis, which we accomplished in early January.  We are also pleased with the continued positive read out of our clinical uveitis data and look forward to presenting these data at upcoming congresses.  Meanwhile, we will continue to refine our go-to-market plan in the U.S. and I am confident we have the experienced team and strategy to execute our launch plan with precision."

Fiscal Second Quarter and Six-Month Results

Revenue for the second fiscal quarter ended December 31, 2017 totaled $933,000 compared to $6.0 million for the prior year quarter. The year-ago second quarter included the recognition of deferred collaborative research and development revenue totaling $5.6 million resulting from termination of the Pfizer collaboration agreement.  Excluding the Pfizer termination, revenue from feasibility study agreements and royalty income increased to $933,000 for the three months ended December 31, 2017 compared to $387,000 in the prior year quarter. Current period revenues included $196,000 of royalty income received from Alimera Sciences, representing the first quarterly reporting under our July 2017 restructured collaboration agreement. Operating expenses for the three months ended December 31, 2017 increased to $6.7 million from $6.1 million a year earlier, due primarily to professional services costs associated with the NDA filing for Durasert three-year uveitis. Net loss for the quarter ended December 31, 2017 was $5.8 million, or $0.13 per share, compared to net loss of $67,000, or break-even per share, for the prior year quarter.

Revenue for the six months ended December 31, 2017 was $1.3 million compared to $6.2 million for the six months ended December 31, 2016. Excluding the $5.6 million revenue recognized in the prior year period upon termination of the Pfizer agreement, revenues from feasibility study agreements and royalty income increased to $1.3 million for the six months ended December 31, 2017 compared to $664,000 in the prior year six-month period. Operating expenses for the first six months of fiscal 2018 were $13.1 million compared to $13.5 million a year earlier. Higher professional services costs related to the Company's NDA filing were substantially offset by the absence in the current year-to-date period of severance costs and professional fees related to the Company's CEO transition and elimination of the position of Vice President, Corporate Affairs and General Counsel in the prior year-to-date period. Net loss for the six months ended December 31, 2017 was $11.8 million, or $0.28 per share, compared to a net loss of $7.2 million, or $0.21 per share for the corresponding fiscal 2017 year-to-date period.

At December 31, 2017, the Company's cash and cash equivalents totaled $12.9 million. 

Anticipated Calendar 2018 Milestones:

  • FDA acceptance for review of the NDA for Durasert three-year treatment for posterior segment uveitis in calendar Q1
  • Present 12-month efficacy and safety data from the second Phase 3 clinical study at leading medical conferences
  • Continue business development efforts and enter into one or more new collaboration agreements with biopharmaceutical companies and other third parties
  • Expect to complete the GLP safety and pharmacokinetic study for a shorter duration product for posterior segment uveitis

Conference Call

pSivida Corp. will host a live webcast and conference call today, February 7, 2018 at 4:30pm ET. The conference call may be accessed by dialing (877) 312-7507 from the U.S. and Canada, or (631) 813-4828 from international locations. The conference ID is 8399835. A live webcast will be available on the Investor Relations section of the corporate website at

A replay of the call will be available beginning February 7, 2018, at approximately 7:30 p.m. ET and ending on February 14, 2018, at 11:59 p.m. ET. The replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, Conference ID Number: 8399835. A replay of the webcast will also be available on the corporate website during that time.

About pSivida Corp.

pSivida Corp. (, headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN ®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert ®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. In January 2018, pSivida filed an NDA with the FDA for its lead product candidate, Durasert™ micro-insert for posterior segment uveitis, which is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint of prevention of recurrence of uveitis at six months of follow-up with statistical significance. pSivida's pre-clinical development program is focused on using its core platform technology Durasert to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit and connect on Twitter, LinkedIn, Facebook and Google+.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; successful commercialization of, and receipt of revenues from, ILUVIEN® for diabetic macular edema ("DME"), which depends on Alimera's ability to continue as a going concern; Alimera's ability to obtain marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN; the number of clinical trials and data required for the Durasert three-year uveitis marketing approval application in the U.S.; acceptance of the Durasert three-year uveitis NDA in the U.S.; our ability to use data in a U.S. NDA from clinical trials outside the U.S.; our ability to successfully commercialize Durasert three-year uveitis, if approved, in the U.S.; potential off-label sales of ILUVIEN for uveitis; consequences of fluocinolone acetonide side effects; the development of our next-generation Durasert shorter-duration treatment for posterior segment uveitis; potential declines in Retisert® royalties; efficacy and the future development of an implant to treat severe osteoarthritis; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements, including our agreement with Alimera; termination or breach of current license agreements, including our agreement with Alimera; our dependence on contract research organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential U.K. exit from the EU; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.


EVC Group

Michael Polyviou/Doug Sherk - Investors;  dsherk@evcgroup.com212.850.6020; 646-445-4800

Thomas Gibson - Media 201-476-0322

  (In thousands, except per share amounts)
          Three Months Ended       Six Months Ended  
          December 31,     December 31,
            2017       2016         2017       2016  
    Collaborative research and development    $   461     $   5,702       $   601     $   5,736  
    Royalty income       472         269           717         512  
      Total revenues       933         5,971           1,318         6,248  
  Operating expenses:                  
    Research and development        4,269         3,165           8,088         7,343  
    General and administrative       2,472         2,900           5,044         6,185  
      Total operating expenses       6,741         6,065           13,132         13,528  
  Loss from operations       (5,808 )       (94 )         (11,814 )       (7,280 )
  Interest and other income       26         27           49         51  
  Net loss   $   (5,782 )   $   (67 )     $   (11,765 )   $   (7,229 )
  Net loss per common share:                  
    Basic and diluted   $   (0.13 )   $   -        $   (0.28 )   $   (0.21 )
  Weighted average common shares outstanding:                
    Basic and diluted       44,530         34,177           41,980         34,176  

  (In thousands)  
          December 31,   June 30,  
            2017       2017    
  Current assets:          
    Cash, cash equivalents and marketable securities $   12,876     $   16,898    
    Other current assets     769         842    
  Total current assets     13,645         17,740    
  Intangible assets, net     -         364    
  Other assets       552         573    
  Total assets   $   14,197     $   18,677    
  Liabilities and stockholders' equity        
  Current liabilities:        
    Accounts payable and accrued expenses $   3,745     $   5,240    
    Deferred revenue     505         50    
  Total current liabilities     4,250         5,290    
  Deferred rent       42         51    
  Total liabilities       4,292         5,341    
  Stockholders' equity:        
    Capital       331,654         323,323    
    Accumulated deficit     (322,585 )       (310,820 )  
    Accumulated other comprehensive income     836         833    
  Total stockholders' equity     9,905         13,336    
  Total liabilities and stockholders' equity $   14,197     $   18,677    



Primary Logo